Furthermore, the number of CTL at the invasive tumor front was prognostic in p16+ tumors (median OS: 41 months vs. NR, p <0.015 and median PFS: 33 months vs. NR, p<0.01). The gene discussed is CDKN2A; the disease is neoplasm.